Dennis A Revicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/851750/publications.pdf

Version: 2024-02-01

41 papers

8,311 citations

346980 22 h-index 355658 38 g-index

41 all docs

41 docs citations

41 times ranked

12359 citing authors

#	Article	IF	CITATIONS
1	Psychometric Properties of the Asthma Symptom Index in Patients with Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 400-409.e1.	2.0	2
2	Evaluating response in gastroparesis: Patient reported outcome measures and survey instruments. , 2021, , 451-460.		O
3	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. Medical Decision Making, 2020, 40, 897-911.	1.2	5
4	Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. Journal of Patient-Reported Outcomes, 2020, 4, 82.	0.9	3
5	Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration. Orphanet Journal of Rare Diseases, 2019, 14, 174.	1.2	10
6	Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. Journal of Patient-Reported Outcomes, 2019, 3, 22.	0.9	11
7	A Scale to Assess Activities of Daily Living in Pantothenate Kinaseâ€Associated Neurodegeneration. Movement Disorders Clinical Practice, 2019, 6, 139-149.	0.8	9
8	The American neurogastroenterology and motility society gastroparesis cardinal symptom indexâ€daily diary (ANMS GCSIâ€DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. Neurogastroenterology and Motility, 2019, 31, e13553.	1.6	14
9	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. Journal of Patient-Reported Outcomes, 2018, 2, 61.	0.9	12
10	Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS $<$ sup $>$ Â $<$ /sup $>$ -Preference (PROPr) Scoring System. Medical Decision Making, 2018, 38, 683-698.	1.2	92
11	Cross-sectional validation of the PROMIS-Preference scoring system. PLoS ONE, 2018, 13, e0201093.	1.1	46
12	Evaluation of options for presenting health-states from PROMIS® item banks for valuation exercises. Quality of Life Research, 2018, 27, 1835-1843.	1.5	14
13	Editorial Comment: "Quantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Maps― Journal of Sexual Medicine, 2017, 14, 160-161.	0.3	0
14	Selection of key health domains from PROMIS® for a generic preference-based scoring system. Quality of Life Research, 2017, 26, 3377-3385.	1.5	39
15	Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29ÂV2.0 Profile Measure to the Health Utilities Index MarkÂ3. Pharmacoeconomics, 2016, 34, 1015-1022.	1.7	45
16	Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2016, 77, 1080-1086.	1.1	6
17	The PROMIS of QALYs. Health and Quality of Life Outcomes, 2015, 13, 122.	1.0	44
18	Adolescent body weight and health-related quality of life rated by adolescents and parents: the issue of measurement bias. BMC Public Health, 2015, 15, 1192.	1.2	15

#	Article	IF	Citations
19	Reliability and Validity of the Work Instability Scale for Rheumatoid Arthritis. Value in Health, 2015, 18, 1008-1015.	0.1	12
20	The Impact of Medication on Health-Related Quality of Life in Patients with Generalized Anxiety Disorder. CNS Drugs, 2015, 29, 29-40.	2.7	8
21	Introduction to special section: quantitative methods. Quality of Life Research, 2015, 24, 1-3.	1.5	15
22	US Valuation of Health Outcomes Measured Using the PROMIS-29. Value in Health, 2014, 17, 846-853.	0.1	117
23	The case for an international patient-reported outcomes measurement information system (PROMIS $\hat{A}^{\text{@}}$) initiative. Health and Quality of Life Outcomes, 2013, 11, 210.	1.0	127
24	Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. Journal of Allergy and Clinical Immunology, 2012, 130, 1078-1084.	1.5	41
25	Humanistic and economic burden of generalized anxiety disorder in North America and Europe. Journal of Affective Disorders, 2012, 140, 103-112.	2.0	117
26	Differential Item Functioning in Quality of Life Measure between Children with and without Special Health-Care Needs. Value in Health, 2011, 14, 872-883.	0.1	20
27	Content Validity of the Female Sexual Function Index (FSFI) in Pre- and Postmenopausal Women with Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2011, 8, 2237-2245.	0.3	42
28	Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials. Quality of Life Research, 2011, 20, 255-262.	1.5	8
29	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 2010, 63, 1179-1194.	2.4	3,521
30	Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Quality of Life Research, 2009, 18, 783-791.	1.5	129
31	Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Quality of Life Research, 2009, 18, 873-880.	1.5	1,272
32	Agreement was not found in adolescents' quality of life rated by parents and adolescents. Journal of Clinical Epidemiology, 2009, 62, 337-346.	2.4	38
33	Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 2009, 24, 289-295.	0.9	40
34	Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Quality of Life Research, 2008, 17, 1285-1294.	1.5	51
35	Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 2008, 61, 102-109.	2.4	1,701
36	Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. Journal of Rheumatology, 2008, 35, 206-15.	1.0	43

#	Article	IF	CITATIONS
37	Clinical Assessment of Asthma Symptom Control: Review of Current Assessment Instruments. Journal of Asthma, 2006, 43, 481-487.	0.9	33
38	Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. Quality of Life Research, 2004, 13, 833-844.	1.5	311
39	Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 769-777.	2.4	79
40	Integrating Patient Preferences Into Health Outcomes Assessment. Chest, 1998, 114, 998-1007.	0.4	215
41	The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study. , 0, , .		4